D-0005-2022 Class II Ongoing

Recalled by RISING PHARMACEUTICALS — East Brunswick, NJ

FDA drug recall D-0005-2022 was initiated by RISING PHARMACEUTICALS on Sep 2, 2021 and is designated Class II. Reason for recall: Labeling: Incorrect Instructions The recall status is ongoing. Affected quantity: 1,344 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 13, 2021
Initiation Date
Sep 2, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,344 bottles

Product description

Meclizine HCl Tablets, 25 mg, packaged in 100-count HDPE bottle, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816, Manufactured by: Aurex laboratories LLC, East Windsor, NJ 08520, NDC 16571-752-01

Reason for recall

Labeling: Incorrect Instructions

Distribution pattern

to be entered

Code information

Lot # CB21024, Exp 2/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0005-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0005-2022. Report a data issue: hello@regdatalab.com.